Европейски съюз -
български -
EMA (European Medicines Agency)
zalviso
fgk representative service gmbh - суфентанил - Болка, следоперативно - Анестезиология - zalviso е показан за лечение на остра умерена до тежка следоперативна болка при възрастни пациенти.
България -
български -
Изпълнителна агенция по лекарствата
octenisept 1 mg/ml + 20mg/ml cutaneous spray, solution
fgk representative service gmbh - 1 mg/ml + 20mg/ml cutaneous spray, solution
Европейски съюз -
български -
EMA (European Medicines Agency)
dovprela (previously pretomanid fgk)
mylan ire healthcare limited - pretomanid - Туберкулоза, мултирезистентни - Антимикобактериални - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). Трябва да се вземат предвид официалните препоръки за правилното използване на антибактериални агенти.
Европейски съюз -
български -
EMA (European Medicines Agency)
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - Лекарства за лечение на костни заболявания - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
Европейски съюз -
български -
EMA (European Medicines Agency)
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - анти-туморни агенти - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Европейски съюз -
български -
EMA (European Medicines Agency)
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - Антинеопластични средства - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Европейски съюз -
български -
EMA (European Medicines Agency)
voxzogo
biomarin international limited - vosoritide - achondroplasia - Лекарства за лечение на костни заболявания - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
България -
български -
БАБХ (Българска агенция по безопасност на храните)
bovilis ibr marker
intervet international b.v. - bovilis герпесвирусу тип 1(|БХВ - 1), на живо, щам gc/Д (fe-) - лиофилизат и разтворител за инжекционна суспензия - мин. 10 на степен 5.7 – мак. 10 на степен 7.3 tcid50 - говеда